Trade Exelixis, Inc. - EXEL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.19 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 35.98 |
| Open | 36.46 |
| 1-Year Change | 62.91% |
| Day's Range | 35.87 - 36.66 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 36.39 | -0.02 | -0.05% | 36.41 | 36.75 | 35.77 |
| Jan 17, 2025 | 36.13 | -0.29 | -0.80% | 36.42 | 36.83 | 35.94 |
| Jan 16, 2025 | 36.36 | -0.84 | -2.26% | 37.20 | 37.25 | 36.36 |
| Jan 15, 2025 | 37.21 | 1.32 | 3.68% | 35.89 | 37.25 | 35.89 |
| Jan 14, 2025 | 35.59 | 0.54 | 1.54% | 35.05 | 35.90 | 34.75 |
| Jan 13, 2025 | 35.21 | -1.04 | -2.87% | 36.25 | 36.25 | 34.33 |
| Jan 10, 2025 | 35.96 | 1.92 | 5.64% | 34.04 | 36.13 | 34.00 |
| Jan 8, 2025 | 34.45 | 0.35 | 1.03% | 34.10 | 34.47 | 33.77 |
| Jan 7, 2025 | 34.17 | 1.29 | 3.92% | 32.88 | 34.44 | 32.88 |
| Jan 6, 2025 | 33.15 | -0.55 | -1.63% | 33.70 | 33.91 | 33.00 |
| Jan 3, 2025 | 33.92 | 0.32 | 0.95% | 33.60 | 34.06 | 33.60 |
| Jan 2, 2025 | 33.89 | 0.49 | 1.47% | 33.40 | 33.91 | 33.32 |
| Dec 31, 2024 | 33.17 | -0.58 | -1.72% | 33.75 | 34.00 | 33.17 |
| Dec 30, 2024 | 33.65 | 0.23 | 0.69% | 33.42 | 34.08 | 33.42 |
| Dec 27, 2024 | 33.70 | -0.07 | -0.21% | 33.77 | 34.17 | 33.59 |
| Dec 26, 2024 | 33.98 | 0.38 | 1.13% | 33.60 | 34.03 | 33.60 |
| Dec 24, 2024 | 33.75 | 0.68 | 2.06% | 33.07 | 33.84 | 33.07 |
| Dec 23, 2024 | 33.41 | 0.13 | 0.39% | 33.28 | 33.53 | 33.04 |
| Dec 20, 2024 | 33.22 | 0.01 | 0.03% | 33.21 | 33.61 | 33.05 |
| Dec 19, 2024 | 33.62 | 0.19 | 0.57% | 33.43 | 34.06 | 32.91 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Exelixis Company profile
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.| Industry: | Bio Therapeutic Drugs |
1851 Harbor Bay Parkway
ALAMEDA
CALIFORNIA 94502
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
15:24, 21 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com